Granules India Limited — Q2FY27 earnings call summary

Filed 06 October 2026 · Official transcript

Granules returned to growth in FY26, starting a new growth cycle
First-to-file strategy progressing with two sole first-to-file ANDAs filed, pipeline for FY30-34
Peptide CDMO targets $50 million revenue run rate by FY29 and $100 million by FY31
FY27 R&D investment at 6% of revenue, supporting differentiated products
Planned capex of Rs 2,000 Cr over 3-4 years for growth areas and digitalization
Gross margin improved 15 percentage points over 4 years; EBITDA margin up 3 points
Four growth engines: controlled substances, complex generics, oncologies, peptide CDMO
Controlled substances business is third largest in US by value, with growing DEA quota